These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 11463019)

  • 21. Responding to hepatitis C through the criminal justice system.
    Rich JD; Allen SA; Williams BA
    N Engl J Med; 2014 May; 370(20):1871-4. PubMed ID: 24827032
    [No Abstract]   [Full Text] [Related]  

  • 22. Managing hepatitis C infection in HIV-positive patients.
    Craven DE; Nunes DP
    AIDS Clin Care; 2000 Sep; 12(9):71-5, 78. PubMed ID: 12170952
    [No Abstract]   [Full Text] [Related]  

  • 23. Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses.
    Lazarus JV; Safreed-Harmon K; Stumo SR; Jauffret-Roustide M; Maticic M; Reic T; Schatz E; Tallada J; Harris M;
    Int J Drug Policy; 2017 Sep; 47():47-50. PubMed ID: 28689856
    [No Abstract]   [Full Text] [Related]  

  • 24. Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities.
    Hagan H; Latka MH; Campbell JV; Golub ET; Garfein RS; Thomas DA; Kapadia F; Strathdee SA;
    Clin Infect Dis; 2006 Mar; 42(5):669-72. PubMed ID: 16447112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C treatment for injection drug users: a review of the available evidence.
    Hellard M; Sacks-Davis R; Gold J
    Clin Infect Dis; 2009 Aug; 49(4):561-73. PubMed ID: 19589081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comment on the updated AASLD practice guidelines for the diagnosis, management, and treatment of hepatitis C: treating active drug users.
    Swan T; Curry J
    Hepatology; 2009 Jul; 50(1):323-4; author reply 324-5. PubMed ID: 19554546
    [No Abstract]   [Full Text] [Related]  

  • 27. Hepatitis C. Shedding light on the shadow epidemic.
    Harv Health Lett; 1999 Jul; 24(9):1-3. PubMed ID: 10368531
    [No Abstract]   [Full Text] [Related]  

  • 28. Hepatitis C: who should we be treating?
    Kirchner JT
    Am Fam Physician; 1999 Jan; 59(2):273-4, 277. PubMed ID: 9930123
    [No Abstract]   [Full Text] [Related]  

  • 29. Side effects. Safety and effectiveness of interferon and ribavirin in HIV+ people co-infected with hepatitis C virus.
    TreatmentUpdate; 2001; 12(8):4-5. PubMed ID: 12132439
    [No Abstract]   [Full Text] [Related]  

  • 30. Hepatitis C: Should antiviral therapy be offered to elderly patients?
    Floreani A
    Nat Rev Gastroenterol Hepatol; 2009 Sep; 6(9):503-4. PubMed ID: 19713980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The politics of place(ment): problematising the provision of hepatitis C treatment within opiate substitution clinics.
    Rance J; Newland J; Hopwood M; Treloar C
    Soc Sci Med; 2012 Jan; 74(2):245-53. PubMed ID: 22133583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current issues in hepatitis C, HIV co-infection discussed at lunch and learn.
    Monarch A
    Surviv News (Atlanta Ga); 2002 Sep; ():14. PubMed ID: 12765135
    [No Abstract]   [Full Text] [Related]  

  • 33. Current challenges in hepatitis C.
    Swan T
    Res Initiat Treat Action; 2004; 10(2):17-20. PubMed ID: 15828096
    [No Abstract]   [Full Text] [Related]  

  • 34. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support.
    Grebely J; Knight E; Genoway KA; Viljoen M; Khara M; Elliott D; Gallagher L; Storms M; Raffa JD; DeVlaming S; Duncan F; Conway B
    Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):270-7. PubMed ID: 20425880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comment on Fabrizi et al.: Treatment of hepatitis C after kidney transplant: A pooled analysis of observational studies.
    Pan YN; Luo YJ; He S
    J Med Virol; 2015 Aug; 87(8):1255. PubMed ID: 26037651
    [No Abstract]   [Full Text] [Related]  

  • 36. Hepatitis C in injection drug users: It is time to treat.
    Grassi A; Ballardini G
    World J Gastroenterol; 2017 May; 23(20):3569-3571. PubMed ID: 28611509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reply to the letter by Pan Yanna et al. 'treatment of hepatitis C after kidney transplant: A pooled analysis of observational studies'.
    Fabrizi F; Messa P; Martin P
    J Med Virol; 2015 Aug; 87(8):1256-7. PubMed ID: 26037652
    [No Abstract]   [Full Text] [Related]  

  • 38. More intensive hepatitis C virus care models promote adherence among people who inject drugs with active drug use: The PREVAIL study.
    Heo M; Pericot-Valverde I; Niu J; Norton BL; Akiyama MJ; Nahvi S; Arnsten JH; Litwin AH
    J Viral Hepat; 2023 Feb; 30(2):172-175. PubMed ID: 36197920
    [No Abstract]   [Full Text] [Related]  

  • 39. Integrating hepatitis C and addiction care for people who inject drugs in the era of direct-acting antiviral therapy.
    Bird K; Socías ME; Ti L
    Int J Drug Policy; 2018 Sep; 59():1-2. PubMed ID: 29960218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Coinfection by human immunodeficiency virus and hepatitis C virus].
    Lana Soto R; Mendoza Hernández JL; Lérida Urteaga AI; Alvarez-Sala Walther JL
    Rev Clin Esp; 1998 Apr; 198(4):237-41. PubMed ID: 9633210
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.